NICE National Institute for Health and Care Excellence

Resource impact summary report

Resource impact
Published: 16 April 2025

www.nice.org.uk

Contents

Resource impact summary report

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect local data and assumptions.

Recommendations

NICE has recommended rucaparib as an option for the maintenance treatment of advanced (International Federation of Gynecology and Obstetrics [FIGO] stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after complete or partial response to first-line platinum-based chemotherapy in adults, only if:

- it is BRCA mutation-negative and homologous recombination deficiency (HRD)-positive, or
- it is BRCA mutation-negative, and HRD status is negative or unknown, and bevacizumab is not a treatment option because:
  - NHS England's BEV3 and BEV10 commissioning approval criteria for having it are not met, or
  - it is contraindicated or not tolerated, and
- the company provides rucaparib according to the commercial arrangement.

These recommendations are not intended to affect treatment with rucaparib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS healthcare professional consider it appropriate to stop.

Eligible population for rucaparib

Table 1 shows the population who are eligible for rucaparib and the number of people who are expected to have rucaparib in each of the next 5 years.

Table 1 Population expected to be eligible for and have rucaparib in England

Eligible population and uptake	Current practice	Year 1	Year 2	Year 3	Year 4	Year 5
People eligible for rucaparib	860	870	880	890	900	900
Uptake for rucaparib (%)	0	30	50	50	50	50
People starting treatment each year	0	260	440	445	450	450
People continuing treatment from previous years	0	0	260	700	890	890
People having rucaparib each year	0	260	700	1,145	1,340	1,340

Treatment options for the eligible population

The comparator treatments for rucaparib were:

- olaparib plus bevacizumab, bevacizumab alone and routine surveillance for the BRCA mutation-negative HRD-positive population
- bevacizumab alone and routine surveillance for the BRCA mutation negative HRD-negative population.

Niraparib is a treatment option that was not included as a comparator because it is not recommended in routine commissioning. But experts, the company and the committee considered that it would be the main alternative to rucaparib in clinical practice because the HRD-negative population can only have rucaparib if bevacizumab is not an option.

For more information about the treatments, such as dose and average treatment duration, see the resource impact template.

Financial resource impact (cash items)

The company has a commercial arrangement. This makes rucaparib available to the NHS with a discount.

Users can input the confidential price of rucaparib and amend other variables in the resource impact template.

The payment mechanism for the technology is determined by the responsible commissioner and depends on the technology being classified as high cost.

For further analysis or to calculate the financial impact of cash items, see the resource impact template.

Capacity impact

Table 2 shows the impact on capacity activity in each of the next 5 years.

Table 2 Capacity impact (activity) in England

Capacity impact	Current practice	Year 1	Year 2	Year 3	Year 4	Year 5
Number of administration appointments	9,300	9,670	10,100	10,500	10,630	10,730

For further analysis or to calculate the financial capacity impact from a commissioner (national) and provider (local) perspective, see the resource impact template.

Key information

Table 3 Key information

Time from publication to routine commissioning funding	90 days
Programme budgeting category	02G cancers and tumours, gynaecological
Commissioner	NHS England
Providers	NHS hospital trusts
Pathway position	Second line

About this resource impact summary report

This resource impact summary report accompanies the NICE technology appraisal guidance on rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy and should be read with it. See terms and conditions and on the NICE website.

ISBN: 978-1-4731-6970-8